Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the A rt and New Perspectives with Patents Recently Applied-Reference-Cited by-同舟云学术

Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the A rt and New Perspectives with Patents Recently Applied

Published:2018-05-11 Issue:2 Volume:13 Page:201-208
ISSN:1574-8928
Container-title:Recent Patents on Anti-Cancer Drug Discovery
language:en
Short-container-title:PRA

Author:

Ferrari Silvia M.¹,Ruffilli Ilaria¹,Centanni Marco²,Virili Camilla²,Materazzi Gabriele³,Alexopoulou Magdalini¹,Miccoli Mario¹,Antonelli Alessandro¹,Fallahi Poupak¹

Affiliation:

1. Department of Clinical and Experimental Medicine, University of Pisa, Via Savi, 10, I-56126, Pisa, Italy

2. Department of Medico-Surgical Sciences and Biotechnologies, "Sapienza" University of Rome, Latina, Italy

3. Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology (medical),Cancer Research,Drug Discovery,Oncology,General Medicine

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer;Expert Opinion on Pharmacotherapy;2024-08-12

2. The potential role of reprogrammed glucose metabolism: an emerging actionable codependent target in thyroid cancer;Journal of Translational Medicine;2023-10-18

3. Antineoplastic Activity of Pazopanib in Anaplastic Thyroid Cancer in Primary Culture;International Journal of Molecular Sciences;2023-01-25

4. Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma;Creative surgery and oncology;2023-01-05

5. Molecular targets for the treatment of angina pectoris;Nanotechnology Principles in Drug Targeting and Diagnosis;2023